Phase 2 Glioblastoma Multiforme Trial Underway

Andrew Black
Published Online: Monday, Feb 13, 2017
DelMar Pharmaceuticals has begun dosing patients in their Phase 2 clinical trial of VAL-083 (dianhydrogalactitol) for the treatment of MGMT-unmethylated recurrent Glioblastoma Multiforme (GBM).
The study is a Phase 2 single arm clinical trial assessing dianhydrogalactitol in patients 18-years and older diagnosed with MGMT unmethylated, Bevacizumab-naive recurrent GBM. Patients will receive 40 mg/m2 of dianhydrogalactitol through IV for 30-60 minutes on days 1, 2, and 3 of a 21-day treatment-cycle, for up to 12, 21-day treatment cycles.
VAL-083 (dianhydrogalactitol) is a small-molecule chemotherapeutic. The drug is deisnged to cross the blood-brain barrier and accumulate in brain tumor tissue. Dianhydrogalactitol’s mechanism of action is bifunctional DNA alkylation at the N7 position of guanine.
The clinical trial is currently enrolling patients, to learn more visit https://clinicaltrials.gov/ct2/show/NCT02717962

About Glioblastoma Multiforme

Glioblastoma multiforme (GBM) is a rare but very aggressive form of brain cancer. Glioblastomas can be classified as primary or secondary. Primary glioblastoma tends to occur in older adults (> 50 years) and appear quite suddenly (less than 3 months from initial symptoms to diagnosis). Secondary glioblastoma is less common and occurs in younger patients (< 45 y). These tumors can be present for years before symptoms appear.
Standard therapy for glioblastoma consists of surgical resection, radiation therapy, and chemotherapy. Patients treated with this standard therapy tend to survive for approximately 12 months. Without treatment, survival is about 3 months.

Latest Articles
Last month, Steve placed first in his division. Two days later, he was busy training for the next contest (May 2017).
Today, the American Health Care Act (aka TrumpCare) is being voted in Congress. The bill needs 215 votes to be approved. It is likely that no Democrats support it, meaning that only 21 Republicans can vote against the bill and it can still get approved.
PANDAS, or pediatric acute-onset neuropsychiatric syndrome, links the sudden onset of OCD or tic-like symptoms to streptococcal-A (GABHS). Could this mysterious affliction be a rare disease or not a disease at all?
To celebrate Rare Disease Day on February 28, 2017, Amicus Therapeutics hosted CabaRare at their Cranbury, N.J. headquarters in which four young people with rare diseases shared their musical talents
$vacMongoViewPlus$ $vAR$